StreetInsider.com News Articles

Guggenheim Starts Ovid Therapeutics Inc (OVID) at Buy

Mon, 05 Oct 2026 16:07:17 -0400

Guggenheim analyst Delma Caiati initiates coverage on Ovid Therapeutics Inc (NASDAQ: OVID) with a Buy rating and a price target of $7.00.

For an analyst ratings summary and ratings history on Ovid Therapeutics Inc click here. For more ratings news on Ovid Therapeutics Inc click here.

Shares of Ovid Therapeutics Inc closed at $2.38 yesterday.

Ovid Therapeutics Inc (OVID) PT Raised to $5 at H.C. Wainwright

Fri, 11 Sep 2026 06:57:54 -0400

(Updated - September 11, 2026 6:57 AM EDT)

H.C. Wainwright analyst Raghuram Selvaraju raised the price target on Ovid Therapeutics Inc (NASDAQ: OVID) to $5.00 (from $4.00) while maintaining a Buy rating.

The analyst commented: "Ovid Therapeutics has received regulatory clearance across multiple regions and has initiated the dose-confirmatory study to evaluate seizure reduction efficacy, safety and tolerability of OV329 in people living with treatment-resistant focal onset seizures (FOS). This global study is designed with registrational-level rigor to potentially support multiple future seizure indications for OV329. The study is slated to be completed in 2H27. Ovid has also received regulatory clearances and

Ovid Therapeutics Inc (OVID) PT Raised to $5 at H.C. Wainwright

Fri, 11 Sep 2026 06:57:54 -0400

(Updated - September 11, 2026 6:57 AM EDT)

H.C. Wainwright analyst Raghuram Selvaraju raised the price target on Ovid Therapeutics Inc (NASDAQ: OVID) to $5.00 (from $4.00) while maintaining a Buy rating.

Ovid Therapeutics to Participate in Upcoming Investor Conferences

Thu, 03 Sep 2026 08:00:00 -0400

NEW YORK, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to pioneering better, gentler medicines for brain disorders with significant unmet need, today announced that the Company’s management will participate in two upcoming investor conferences:

Cantor Global Healthcare Conference – Wednesday, September 9 at 2:10 pm ET
H.C. Wainwright 28th Annual Global Investment Conference – Monday, September 14 at 11:30 am ET

Webcasts of the presentations can be accessed through the Events & Presentations section of the company’s website at investors.ovidrx.com. An archived replay

Ovid Therapeutics to Participate in Upcoming Investor Conferences

Thu, 03 Sep 2026 08:00:00 -0400

Cantor Global Healthcare Conference – Wednesday, September 9 at 2:10 pm ET
H.C. Wainwright 28th Annual Global Investment Conference – Monday, September 14 at 11:30 am ET

Webcasts of the presentations can be accessed through the Events & Presentations section of the company’s website at investors.ovidrx.com. An archived replay

Form 144 Ovid Therapeutics Inc. Filed by: Rona Jeffrey A

Mon, 24 Aug 2026 16:48:00 -0400

si-local-file:///var/storage/secattach/20260824/26968757.html

Form 144 Ovid Therapeutics Inc. Filed by: Rona Jeffrey A

Mon, 24 Aug 2026 16:48:00 -0400

si-local-file:///var/storage/secattach/20260824/26968757.html

Form 144 Ovid Therapeutics Inc. Filed by: Rona Jeffrey A

Fri, 14 Aug 2026 18:28:00 -0400

si-local-file:///var/storage/secattach/20260814/26933134.html

Form 144 Ovid Therapeutics Inc. Filed by: Rona Jeffrey A

Fri, 14 Aug 2026 18:28:00 -0400

si-local-file:///var/storage/secattach/20260814/26933134.html

Form SCHEDULE 13G/A Ovid Therapeutics Inc. Filed by: ADAR1 Capital Management, LLC

Fri, 14 Aug 2026 17:07:00 -0400

si-local-file:///var/storage/secattach/20260814/26932618.html

Form SCHEDULE 13G/A Ovid Therapeutics Inc. Filed by: ADAR1 Capital Management, LLC

Fri, 14 Aug 2026 17:07:00 -0400

si-local-file:///var/storage/secattach/20260814/26932618.html

Form SCHEDULE 13G/A Ovid Therapeutics Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.

Fri, 14 Aug 2026 16:49:00 -0400

si-local-file:///var/storage/secattach/20260814/26932169.html

Form SCHEDULE 13G/A Ovid Therapeutics Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.

Fri, 14 Aug 2026 16:49:00 -0400

si-local-file:///var/storage/secattach/20260814/26932169.html

Form SCHEDULE 13G/A Ovid Therapeutics Inc. Filed by: EVENTIDE ASSET MANAGEMENT, LLC

Fri, 14 Aug 2026 11:42:00 -0400

si-local-file:///var/storage/secattach/20260814/26927346.html

Form SCHEDULE 13G/A Ovid Therapeutics Inc. Filed by: EVENTIDE ASSET MANAGEMENT, LLC

Fri, 14 Aug 2026 11:42:00 -0400

si-local-file:///var/storage/secattach/20260814/26927346.html

Form SCHEDULE 13G/A Ovid Therapeutics Inc. Filed by: BALYASNY ASSET MANAGEMENT L.P.

Fri, 14 Aug 2026 06:09:00 -0400

si-local-file:///var/storage/secattach/20260814/26924137.html

Form SCHEDULE 13G/A Ovid Therapeutics Inc. Filed by: BALYASNY ASSET MANAGEMENT L.P.

Fri, 14 Aug 2026 06:09:00 -0400

si-local-file:///var/storage/secattach/20260814/26924137.html

Form SCHEDULE 13G/A Ovid Therapeutics Inc. Filed by: Affinity Asset Advisors, LLC

Thu, 13 Aug 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260813/26921002.html

Form SCHEDULE 13G/A Ovid Therapeutics Inc. Filed by: Affinity Asset Advisors, LLC

Thu, 13 Aug 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260813/26921002.html

Form 10-Q Ovid Therapeutics Inc. For: Jun 30

Thu, 13 Aug 2026 08:33:00 -0400

si-local-file:///var/storage/secattach/20260813/26917138.html

Form 10-Q Ovid Therapeutics Inc. For: Jun 30

Thu, 13 Aug 2026 08:33:00 -0400

si-local-file:///var/storage/secattach/20260813/26917138.html

Form 8-K Ovid Therapeutics Inc. For: Aug 11

Thu, 13 Aug 2026 08:32:00 -0400

si-local-file:///var/storage/secattach/20260813/26917130.html

Form 8-K Ovid Therapeutics Inc. For: Aug 11

Thu, 13 Aug 2026 08:32:00 -0400

si-local-file:///var/storage/secattach/20260813/26917130.html

Ovid Therapeutics Reports Business Updates and Second Quarter 2026 Financial Results

Thu, 13 Aug 2026 08:30:00 -0400

First-ever oral direct KCC2 activator, OV4071, advancing in an ongoing Phase 1 study
Initiated Phase 2 proof-of-concept and photosensitivity studies for OV329, a next-generation GABA-AT inhibitor
A newly-formed portfolio company with funds advised by Perceptive Advisors acquired global rights to soticlestat; Ovid secured equity in the company and the potential to receive regulatory and sales milestone payments and royalties upon success
Strengthened executive leadership team with appointment of Kevin Norrett as Chief Business Officer and Eliseo Salinas, MD, as Executive R&D Advisor
Cash, cash equivalents and marketable securities were $169.8 million as of June 30, 2026; expected financial runway into 2029
Ovid Therapeutics Reports Business Updates and Second Quarter 2026 Financial Results

Thu, 13 Aug 2026 08:30:00 -0400
- First-ever oral direct KCC2 activator, OV4071, advancing in an ongoing Phase 1 study
- Initiated Phase 2 proof-of-concept and photosensitivity studies for OV329, a next-generation GABA-AT inhibitor
- A newly-formed portfolio company with funds advised by Perceptive Advisors acquired global rights to soticlestat; Ovid secured equity in the company and the potential to receive regulatory and sales milestone payments and royalties upon success
- Strengthened executive leadership team with appointment of Kevin Norrett as Chief Business Officer and Eliseo Salinas, MD, as Executive R&D Advisor
- Cash, cash equivalents and marketable securities were $169.8 million as of June 30, 2026; expected financial runway into 2029